Earlier this month, a judge denied hedge fund billionaire Bill Ackman and Valeant Pharmaceuticals' motion to put a year-old insider-trading case against them to bed. Valeant has a long list of problems: a stock price crushed in four weeks, a too-close relationship with a shady distributor, probes into its patient-assistance programs by two state attorneys, and a US Senate inquiry into its price increases.